21:54:32 EST Wed 18 Nov 2026
Enter Symbol
or Name
USA
CA



Arch Biopartners Inc
Symbol ARCH
Shares Issued 67,933,289
Close 2026-11-18 C$ 0.94
Market Cap C$ 63,857,292
Recent Sedar+ Documents

Arch Biopartners hires Oak Hill for IR services

2026-11-18 19:28 ET - News Release

Mr. Aaron Benson reports

ARCH BIOPARTNERS ENGAGES OAK HILL FINANCIAL INC. FOR INVESTOR RELATIONS AND MARKETING SERVICES

Arch Biopartners Inc. has engaged Oak Hill Financial Inc. to provide investor relations and marketing services, effective Nov. 18, 2026.

Under the engagement, Oak Hill will conduct outreach to investment advisers, institutions and other relevant market participants, support the development of the company's investor messaging, identify existing and prospective investors, and provide regular strategy, feedback and activity reporting. These services are intended to broaden awareness of the company's kidney drug development programs within the investment community.

The agreement has an initial term of three months and will automatically renew for successive one-month periods thereafter unless terminated in accordance with its terms. Either party may terminate the agreement at the end of the initial term or any renewal term by providing at least five days written notice.

The company will pay Oak Hill a monthly advisory fee of $12,000 plus applicable taxes and preapproved out-of-pocket expenses, to be paid from the company's working capital. Oak Hill will not receive any common shares or other securities of the company as compensation. Oak Hill and its principals have advised that they do not currently have any interest, directly or indirectly, in the securities of the company, or any right or intent to acquire such an interest. Oak Hill is an arm's-length party to the company. The engagement is subject to approval by the TSX Venture Exchange.

About Arch Biopartners Inc.

Arch Biopartners is a therapeutic biotechnology company developing on-target drugs for acute kidney injury and chronic kidney disease. The company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.

Arch's development pipeline includes:

  • LSALT peptide: in a phase 2 trial targeting cardiac surgery-associated AKI;
  • Cilastatin: a repurposed drug in a phase 2 trial targeting toxin-induced AKI;
  • CKD platform: next-generation therapeutics targeting chronic kidney disease.

These assets represent distinct, mechanism-based approaches to protecting the kidney from common causes of acute and chronic damage. Chronic kidney disease affects approximately 800 million people worldwide while acute kidney injury adds a further significant burden. Together, Arch's programs target unmet needs across both acute and chronic kidney disease.

Both phase 2 programs are currently enrolling patients at Canadian clinical sites, with an additional Canadian site in development and a U.S. expansion of the CS-AKI trial under way.

The company has 67,933,289 common shares outstanding.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.